For the first time this year, highly pathogenic avian influenza has been detected in Texas dairy cattle, according to a press release this week from the Texas Animal Health Commission (TAHC) and according to the US Department of Agriculture’s (USDA’s) Animal and Plant Health Inspection Service (APHIS).

“The dairy is currently under quarantine as part of existing response protocols, and state and federal officials are working closely to mitigate disease spread,” TAHC said. “According to USDA APHIS, there is no concern that this circumstance poses a risk to consumer health or the safety of the commercial milk supply.”

TAHC said milk from affected animals is being diverted from the commercial milk tank or destroyed so that it does not enter the human food supply.

H5N1 detected at commercial duck meat facility 

In related news, APHIS has tracked avian flu in Idaho cattle throughout May. In total, 15 dairies in Idaho (14) and Texas (one) have confirmed cases in the past 30 days. 

In other avian flu news, Indiana is the only state in the past two weeks reporting H5N1 detections on commercial country farms, according to APHIS. The most recent positive samples were from Elkhart County, in an outbreak involving 3,100 birds at a commercial duck meat facility. 

In the past 30 days, avian flu has been confirmed in 24 flocks (16 commercial, 8 backyard), affecting 280,000 birds. 

• Indian drugmaker Wockhardt announced earlier this week that the US Food and Drug Administration (FDA) has approved its novel intravenous antibiotic for complicated urinary tract infections (cUTIs), including pyelonephritis, in adults. Marketed under the brand name Zaynich, the drug combines the cephalosporin antibiotic cefepime with zidebactam, a beta-lactamase inhibitor. Company officials say it will provide an additional option for treating cUTIs caused by multidrug-resistant bacteria. “The threat of drug-resistant infections is an escalating crisis, leaving clinicians with fewer tools to treat patients facing these aggressive pathogens,” Wockhardt Chief Medical Officer Dennis Deruelle, MD, said in a company press release. “The FDA approval of Zaynich is a monumental step forward in validating a new option for these underserved populations.”
• The World Health Organization (WHO) will convene a group of experts to develop guidelines for the use of two new oral antibiotics for gonorrhea. The experts will meet later this year to consider whether zoliflodacin and gepotidacin, both approved by the FDA in December 2025, should be recommended for the treatment of uncomplicated urogenital gonorrhea. The WHO said in a news release that the emergence of gonorrhea strains that are resistant to ceftriaxone, which is the last reliable first-line treatment in most settings, “makes the integration of new treatment options an urgent priority.”   
• A new report from the Food and Agriculture Organization of the United Nations suggests that, under current trends, global antimicrobial use in livestock is projected to grow 30% by 2040 compared with 2019, driven by demand for meat in emerging economies. The report argues that while use of antimicrobial growth promoters leads to measurable short-term productivity gains in livestock and phasing out such use will create an immediate economic shock, rising rates of antimicrobial resistance (AMR) will have a bigger economic impact, with cumulative production losses under a high-AMR scenario reaching $318 billion by 2040. The report concludes that phase-out policies “should combine restrictions with practical measures that accelerate the availability and adoption of effective alternatives, strengthen animal health services, and reduce disease pressure at the farm level.”